Report
EUR 14.31 For Business Accounts Only

MEDICAL DATA VISION sees an upgrade to Slightly Negative thanks to a better star rating, but the title remains unattractive

The independent financial analyst theScreener just awarded an improved star rating to MEDICAL DATA VISION (JP), active in the Medical Equipment industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date February 25, 2022, the closing price was JPY 1,045.00 and its target price was estimated at JPY 821.78.
Underlying
Medical Data Vision

Medical Data Vision Co Ltd. Medical Data Vision Co.,Ltd. is a company engaged in the medical data network business. The Data Network Service provides management support systems for medical institutions and health insurance unions, as well as EVE, Medical Code and CADA-BOX for hospitals. The Data Utilization Service provides corporate services and personal services based on the medical and health information accumulated through the data network services, various analysis data to pharmaceutical companies, research institutes, patients and consumers. The segment provides various services, such as MDV analyzer, ADHOC research service, OTC, H&BC and insurance company services, as well as Media logs and others.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch